2 / 6
Volume 3
Diagnostic Pathology: Open Access
ISSN: 2476-2024
Laboratory Medicine 2018
June 25-26, 2018
Page 36
conference
series
.com
June 25-26, 2018 | Berlin, Germany
13
th
International Conference on
Laboratory Medicine & Pathology
Petr Starostik, Diagn Pathol Open 2018, Volume 3
DOI: 10.4172/2476-2024-C1-001
Personalized pharmacogenomics
G
atorSeq Pharm is a pharmacogenomic gene assay we developed that predicts how patients will respond to a specific drug. The
test determines the genotype/allelotype of each patient and correlates the results with the expected drug response based on
published data and Clinical Pharmacogenetics Implementation Consortium recommendations. Personalized drug therapy can then
be based on the individual’s genetic makeup which accounts for differences in drug absorption, metabolism, and efficiency. Such
genetic differences may explain why one drug works well for one person, but the same drug causes severe adverse effects in other
individuals. The test was validated in a clinical CLIA-approved laboratory to genotype 11 most significant pharmacogenomic genes.
The test results provides the ordering physician with actionable relevant data and recommendations to individualize patient care
allowing them to make insightful treatment decisions.
Biography
Dr. Petr Starostik isAssociate Professor of Pathology and serves as Director of Molecular Pathology in the Department of Pathology, Immunology, and Laboratory Medicine
of the College of Medicine at the University of Florida in Gainesville, FL. Over the years, he directed several molecular diagnostics laboratories, both in the U.S. and abroad.
Development of molecular diagnostic tests is his specialty as evidenced by his publications and the multitude of laboratory-developed tests performed in laboratories he
directed. Besides clinical work, he also pursues basic research focusing on the role of FLT3 ITD in acute leukemia.
starostik@pathology.ufl.eduPetr Starostik
University of Florida, USA